EGFR and neoplasm: In contrast to the cancer-promoting epidermal growth factor receptor (EGFR), EphA2 exerts tumor-suppressive effects through the ligand-dependent tyrosine phosphorylation (pY588) of specific tyrosine residues in the presence of its ligand.